Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-018 vs BAT in Myelofibrosis with Severe Thrombocytopenia
NCT04854096Phase 2Terminated
- Sponsor
- NS Pharma, Inc.
- Start
- Jan 2023
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 9
01
Overview
Phase 2, randomised, open-label trial of ilginatinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and post-essential thrombocythemia myelofibrosis (PET-MF) (2 arms), sponsored by NS Pharma, Inc. Primary endpoints: Change in Spleen Volume at 24 weeks and Change in Total Symptom Score at 24 weeks. Started Jan 2023; status: terminated.
02
Drugs
ilginatinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT04854096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04854096.